- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05878288
Dyb sekventering i kutane pladecellecarciNomer (DISCERN)
Omfattende og dyb profilering i kutane pladecellecarcinomer for at afsløre behandlingseffektivitet hos immunterapibehandlede patienter
To comprehensively describe the molecular profile of the tumour ecosystem of cutaneous squamous cell carcinoma (CSCC) patients treated with neoadjuvant immunotherapy using single-cell sequencing and bulk genomic profiling.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
The purpose of this study is to comprehensively assess the molecular profile of the tumour ecosystem of CSCC patients who receive immunotherapy in the neoadjuvant curative setting, in order to identify molecular mechanisms facilitating treatment response and resistance and to identify molecular markers for disease monitoring. Patients who receive immunotherapy for the neoadjuvant management of CSCC will be invited to participate in this translational research study during their treatment journey to provide tumour tissue (fresh and formal-fixed paraffin-embedded, FFPE) and blood samples before and after exposure to immunotherapy.
This study has primarily a translational research objective with the clinical component conducted as a prospective, single-centre, single-arm, open label study.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
Victoria
-
Melbourne, Victoria, Australien, 3000
- Peter MacCallum Cancer Centre
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Stage II to IV (M0) CSCC who are candidates for surgery, but who have an increased risk of recurrence and/or risk of disfigurement or loss of function. Patients with stage III or IV (M0) CSCC of the head/neck, extremity, or trunk are eligible, and patients with stage II CSCC (≥3 cm longest diameter in an aesthetically sensitive region).
-
At least one measurable lesion per RECIST 1.1.
-
Age ≥18 years.
-
Histologically confirmed diagnosis of invasive CSCC.
-
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
-
Anticipated life expectancy >12 weeks.
-
Adequate organ function defined as:
i) Hepatic function:
- Total bilirubin ≤1.5× upper limit of normal (ULN).
- Patients with Gilbert's Disease and total bilirubin up to 3× ULN are eligible.
- Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) ≤3× ULN.
- Alkaline phosphatase (ALP) ≤2.5× ULN. ii) Renal function: Serum creatinine ≤2× ULN or estimated creatinine clearance >35 mL/min (according the method of Cockcroft and Gault). iii) Creatinine phosphokinase (CPK) (also known as CK [creatinine kinase]) elevation ≤ grade 2. iv) Bone marrow function:
- Haemoglobin ≥9.0 g/dL.
- Absolute neutrophil count (ANC) ≥1.5 x 109/L.
- Platelet count ≥75 x 109/L.
Exclusion Criteria:
- Active solid malignancy or haematological malignancies including chronic lymphocytic leukaemia, (unless indolent or non-life-threatening) within the last 5 years. For clarity, exceptions include other non-melanoma skin cancer that has undergone potentially curative therapy, or in-situ cervical carcinoma or in-situ prostate cancer with non-detectable prostate specific antigen or any other tumour that has been treated, and the patient is deemed to be in complete remission for at least 2 years prior to enrolment.
- Metastatic disease.
- Steroid use >10mg prednisone per day within 14 days of study drug (except if physiologic replacement).
- Active autoimmune disease requiring active systemic therapy within the last 5 years.
- Interstitial lung disease or pneumonitis requiring systemic therapy in the last 5 years.
- Active infection requiring therapy including human immunodeficiency virus (HIV)-1 or HIV-2 serum antibody, hepatitis B virus (HBV), or hepatitis C virus (HCV), or active tuberculosis.
- Breast-feeding or positive serum pregnancy test consistent with pregnancy (excluding false positives defined as a failure of βHCG doubling in 48 hours) or inability to comply with recommended contraception.
- Receipt of live vaccine (including attenuated) within 30 days of first study treatment.
- Prior transplant recipient (corneal transplant patients are eligible).
- Prior PD-L1/PD-1 inhibitor exposure for the same lesion as enrolment.
- Squamous cell carcinoma of unknown primary (those with presumed clinical assessment of CSCC are eligible).
- Any anticancer treatment other than radiation therapy (such as chemotherapy, targeted systemic therapy, imiquimod, photodynamic therapy), either investigational or standard of care, within 30 days of the initial administration of cemiplimab or planned to occur during the study period.
- History of documented allergic reactions or acute hypersensitivity reaction attributed to antibody treatments.
- Patients with allergy or hypersensitivity to cemiplimab or to any of the excipients must be excluded.
- Institutionalised patients by order of judicial or administrative authority.
- Not willing to comply with all study related procedures, particularly consent for collection of tumour and blood samples and imaging, at all protocol specified time points.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Andet
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Andet: Cemiplimab
Cemiplimab 350 mg intravenously every 3 weeks for up to 12 weeks (up to 4 doses), or until unacceptable toxicity, disease progression, or withdrawal of consent. |
Cemiplimab 50 mg/mL supplied as a sterile liquid in single-use glass vials.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Rate of successful execution and generation of data from single-cell RNA sequencing and genomic profiling (including whole exome sequencing, RNA sequencing and immunohistochemistry) of CSCC from patients treated with immunotherapy
Tidsramme: At 72 months
|
Generation of analyzable data from single-cell RNA sequencing and genomic profiling |
At 72 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
At evaluere patologiske responsrater (cPR, mPR defineret som <10 % levedygtig tumor og andet).
Tidsramme: Estimeret 48 måneder
|
Estimeret 48 måneder
|
|
For at evaluere ORR ved hjælp af computertomografi (CT) scanningsbilleddannelse vurderet af RECIST 1.1
Tidsramme: Estimeret 48 måneder
|
Estimeret 48 måneder
|
|
For at evaluere ORR ved hjælp af computertomografi (CT) scanningsbilleddannelse vurderet af imRECIST
Tidsramme: Estimeret 48 måneder
|
Estimeret 48 måneder
|
|
For at opsummere immunrelaterede bivirkninger (AE) > grad 2, AESI, AE'er > grad 3 og SAE'er i henhold til CTCAE v5.0.
Tidsramme: 72 måneder
|
72 måneder
|
|
For at evaluere DFS-rater.
Tidsramme: Estimeret 48 måneder
|
Estimeret 48 måneder
|
|
For at evaluere OS-rater.
Tidsramme: Estimeret 48 måneder
|
Estimeret 48 måneder
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Beskriv om genomiske ændringer identificeret i CSCC og TME kan påvises i cfDNA og fuldblod, og om disse korrelerer med behandlingsrespons.
Tidsramme: 72 måneder
|
72 måneder
|
|
|
Beskriv molekylære mekanismer, der ligger til grund for respons på immunterapi i CSCC ved at sammenligne tumor- og TME-profiler fra immunterapi-respondere vs non-responders defineret ved hjælp af patologisk respons og CT-billeddannelse, for at identificere formodede prædiktive biomarkører.
Tidsramme: 72 måneder
|
72 måneder
|
|
|
To describe any changes in the extent of surgical plans with the use of neoadjuvant immunotherapy, comparing plans at baseline and following neoadjuvant therapy.
Tidsramme: Estimated 48months
|
This outcome will be descriptive. |
Estimated 48months
|
|
Describe molecular mechanisms underlying resistance to immunotherapy in CSCC by comparing tumour and TME profiles from immunotherapy responders vs nonresponders defined using pathological response and CT imaging, to identify putative therapeutic targets.
Tidsramme: 72 months
|
The outcome will be descriptive. |
72 months
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Annette M Lim, MBBS, FRACP, PhD, Peter MacCallum Cancer Centre, Australia
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- HREC/88736/PMCC-2022-326880
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .